The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Two Chemotherapy Regimens Plus or Minus Bevacizumab
Official Title: Randomized Phase 2 Trial Of Two Chemotherapy Regimens Plus Or Minus Bevacizumab In Patients With Well Differentiated Pancreatic Neuroendocrine Tumors
Study ID: NCT03351296
Brief Summary: Compare the effect of capecitabine (cape) + temozolomide (temo) and of 5FU + streptozotocin (strepto) given with a new schedule (LV5FU2 + strepto), two of the most used chemotherapy regimens in the treatment of well differentiated pancreatic neuroendocrine tumors alone or in combination with bevacizumab (beva) on progression-free survival (PFS) and compare the chemotherapy regimens alone or with beva (two by two design) on the same criteria.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Centre Antoine Lacassagne, Nice, Alpes-Maritimes, France
CHU de Caen, Caen, Calvados, France
CHU de Dijon, Dijon, Côte d'Or, France
Hôpital Haut-Lévêque, Pessac, Gironde, France
IUCT - Hôpital Rangueil, Toulouse, Haute-Garonne, France
Hôpital Beaujon, Clichy, Hauts-de-Seine, France
ICM Val d'Aurelle, Montpellier, Hérault, France
Hôpital Trousseau CHU Tours, Chambray-lès-Tours, Indre-et-Loire, France
Institut de Cancérologie de l'Ouest site René Gauducheau, Saint-Herblain, Loire-Atlantique, France
CHR d'Orléans, Orléans, Loiret, France
CHU Angers, Angers, Maine-et-Loire, France
Hôpital Haut-Lévêque, Reims, Marne, France
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France
Hôpital Edouard Herriot, Lyon, Rhône, France
Gustave Roussy, Villejuif, Val De Marne, France
Hôpital Croix St Simon, Paris, , France
Hôpital Saint-Antoine, Paris, , France
Hôpital Cochin, Paris, , France
Hôpital Européen Georges Pompidou, Paris, , France
Centre Eugène Marquis, Rennes, Île-et-Vilaine, France